Literature DB >> 22036515

Requirements for immune recognition and processing of factor VIII by antigen-presenting cells.

Simon D van Haren1, Aleksandra Wroblewska, Kathelijn Fischer, Jan Voorberg, Eszter Herczenik.   

Abstract

Generation of inhibitory antibodies upon repeated FVIII infusion represents a major complication in hemophilia care. Professional antigen presenting cells (APCs) are crucial for orchestration of humoral immune responses. APCs are capable of internalizing soluble as well as particulate antigens through various mechanisms resulting in loading of antigen-derived peptides on MHC class I or II for presentation to T cells. This review highlights how FVIII is recognized and processed by APCs. The significance and contribution of candidate receptors involved in FVIII uptake by APC are discussed. Recent findings defining the repertoire of FVIII peptides presented on MHC class II are addressed. Studies in murine models of hemophilia A suggest that modulation of APC function can reduce inhibitor formation. Based on this we anticipate that modulation of FVIII uptake by APCs may yield novel therapeutic approaches for treatment or prevention of inhibitor formation in patients with hemophilia A.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22036515     DOI: 10.1016/j.blre.2011.10.001

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  7 in total

1.  Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.

Authors:  Devi Gunasekera; Ruth A Ettinger; Shelley Nakaya Fletcher; Eddie A James; Maochang Liu; John C Barrett; Janice Withycombe; Dana C Matthews; Melinda S Epstein; Richard J Hughes; Kathleen P Pratt
Journal:  Blood       Date:  2015-01-23       Impact factor: 22.113

2.  Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.

Authors:  Aleksandra Wroblewska; Simon D van Haren; Eszter Herczenik; Paul Kaijen; Aleksandra Ruminska; Sheng-Yu Jin; X Long Zheng; Maartje van den Biggelaar; Anja ten Brinke; Alexander B Meijer; Jan Voorberg
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

3.  A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.

Authors:  Henning R Stennicke; Marianne Kjalke; Ditte M Karpf; Kristoffer W Balling; Peter B Johansen; Torben Elm; Kristine Øvlisen; Flemming Möller; Heidi L Holmberg; Charlotte N Gudme; Egon Persson; Ida Hilden; Hermann Pelzer; Henrik Rahbek-Nielsen; Christina Jespersgaard; Are Bogsnes; Anette A Pedersen; Anne K Kristensen; Bernd Peschke; Wendy Kappers; Frederik Rode; Lars Thim; Mikael Tranholm; Mirella Ezban; Eva H N Olsen; Søren E Bjørn
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

Review 4.  Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.

Authors:  Pauline A van Schouwenburg; Theo Rispens; Gerrit Jan Wolbink
Journal:  Nat Rev Rheumatol       Date:  2013-02-12       Impact factor: 20.543

Review 5.  Progress toward inducing immunologic tolerance to factor VIII.

Authors:  David W Scott; Kathleen P Pratt; Carol H Miao
Journal:  Blood       Date:  2013-03-15       Impact factor: 22.113

Review 6.  Tolerating Factor VIII: Recent Progress.

Authors:  Sebastien Lacroix-Desmazes; Jan Voorberg; David Lillicrap; David W Scott; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-01-10       Impact factor: 7.561

Review 7.  To clear or to fear: An innate perspective on factor VIII immunity.

Authors:  Jesse Derek Lai; Maria Teofana Georgescu; Christine Hough; David Lillicrap
Journal:  Cell Immunol       Date:  2015-10-28       Impact factor: 4.868

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.